News & Updates
Showing Multidisciplinary articles
Showing

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.

Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression
The extended-release combination of naltrexone and bupropion (NB-ER) may be used as safe and effective treatment for weight reduction among individuals with overweight/obesity and mild to moderate symptoms of depression, suggests a study.

Esketamine, rTMS and ECT: Which is more cost-effective in treatment-resistant depression?
Esketamine is more cost-effective than transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), but not when compared with other commonly used third-line treatments for treatment-resistant depression (TRD) in Hong Kong, a multi-armed modelling study has shown.





